Cite
HARVARD Citation
Patel, S. et al. (n.d.). 3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). European journal of cancer. pp. S689-. [Online].